TY - JOUR
T1 - Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant
AU - Cherng, Hua Jay J.
AU - Xu, Guofan
AU - Feng, Lei
AU - Steiner, Raphael
AU - Fayad, Luis
AU - Strati, Paolo
AU - Nair, Ranjit
AU - Nastoupil, Loretta J.
AU - Lee, Hun Ju
AU - Neelapu, Sattva S.
AU - Flowers, Christopher R.
AU - Rodriguez, Maria
AU - Wang, Michael
AU - Hagemeister, Fredrick
AU - Pinnix, Chelsea C.
AU - Ramdial, Jeremy
AU - Srour, Samer
AU - Nieto, Yago
AU - Rezvani, Katayoun
AU - Champlin, Richard
AU - Kebriaei, Partow
AU - Westin, Jason
AU - Macapinlac, Homer A.
AU - Shpall, Elizabeth
AU - Ahmed, Sairah
N1 - Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2023/1
Y1 - 2023/1
N2 - Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative treatment for patients with relapsed or refractory large B-cell lymphoma (rrLBCL) with chemosensitive disease. A18F-fluorodeoxyglucose positron emission tomography (PET) scan after salvage chemotherapy is used to assess response and eligibility for ASCT, but metrics for chemosensitivity in patients with residual disease are not well defined. We performed a single-centre retrospective analysis of 92 patients with a partial response or stable disease after salvage chemotherapy for rrLBCL who received ASCT to investigate PET-derived parameters and their prognostic utility. The Deauville 5-point Scale (D-5PS) score, maximum standardised uptake value (SUVmax), total metabolic tumour volume (TMTV), and total lesion glycolysis (TLG) were calculated from the post-salvage/pre-ASCT PET scan. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 40% and 54% respectively. A D-5PS score of 5 (p = 0.0082, hazard ratio [HR] 2.09), high SUVmax (p = 0.0015, HR 2.48), TMTV (p = 0.035, HR 1.83) and TLG (p = 0.0036, HR 2.27) were associated with inferior PFS. A D-5PS score of 5 (p = 0.030, HR 1.98) and high SUVmax (p = 0.0025, HR 2.55) were associated with inferior OS. PET-derived parameters may help prognosticate outcomes after ASCT in patients with rrLBCL with residual disease after salvage chemotherapy.
AB - Salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) is a potentially curative treatment for patients with relapsed or refractory large B-cell lymphoma (rrLBCL) with chemosensitive disease. A18F-fluorodeoxyglucose positron emission tomography (PET) scan after salvage chemotherapy is used to assess response and eligibility for ASCT, but metrics for chemosensitivity in patients with residual disease are not well defined. We performed a single-centre retrospective analysis of 92 patients with a partial response or stable disease after salvage chemotherapy for rrLBCL who received ASCT to investigate PET-derived parameters and their prognostic utility. The Deauville 5-point Scale (D-5PS) score, maximum standardised uptake value (SUVmax), total metabolic tumour volume (TMTV), and total lesion glycolysis (TLG) were calculated from the post-salvage/pre-ASCT PET scan. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 40% and 54% respectively. A D-5PS score of 5 (p = 0.0082, hazard ratio [HR] 2.09), high SUVmax (p = 0.0015, HR 2.48), TMTV (p = 0.035, HR 1.83) and TLG (p = 0.0036, HR 2.27) were associated with inferior PFS. A D-5PS score of 5 (p = 0.030, HR 1.98) and high SUVmax (p = 0.0025, HR 2.55) were associated with inferior OS. PET-derived parameters may help prognosticate outcomes after ASCT in patients with rrLBCL with residual disease after salvage chemotherapy.
KW - Deauville 5-point Scale
KW - autologous stem cell transplantation
KW - large B-cell lymphoma
KW - positron emission tomography (PET) scan
KW - quantitative
KW - residual disease
UR - http://www.scopus.com/inward/record.url?scp=85137415013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137415013&partnerID=8YFLogxK
U2 - 10.1111/bjh.18441
DO - 10.1111/bjh.18441
M3 - Article
C2 - 36068929
AN - SCOPUS:85137415013
SN - 0007-1048
VL - 200
SP - 35
EP - 44
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -